Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
FuelCell Energy Reports Fourth Quarter and Full Fiscal Year 2024 Results
-
XOMA Royalty Declares Quarterly Preferred Stock Dividends
-
SweetWater Brewing Announces 28th Anniversary Bash With STS9 Headlining an Immersive Jamtronica Experience
-
Stardust Power Appoints Martyn Buttenshaw to Board of Directors
-
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
-
Correction: Annual Report 2023/24
-
El Sapo Pepe $PEPE: The First Pepe That Inspired Matt Furie's Pepe
-
El Sapo Pepe $PEPE: The First Pepe That Inspired Matt Furie's Pepe
-
Microbix Reports Record Product Sales for Q4 and Fiscal 2024
-
EnviroGold Global Announces Private Placement
-
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
-
Holding(s) in Company
-
NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate
-
BexBack Futures Exchange: 100% Deposit Bonus and No KYC—The Freedom Every Trader Deserves
-
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
-
Western Investment Company Closes Outstanding $1.1 Million of the $30 Million Over-Subscribed Private Placement
-
Nevada Lithium Announces Conditional Approval of TSX Venture Exchange Uplisting
-
XORTX Strengthens Executive Team
-
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
-
Lantronix to Present at the 27th Annual Needham Growth Conference on Jan. 14–15, 2025
-
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
-
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
-
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
-
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
-
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
-
Arbor Biotechnologies Announces FDA Acceptance of IND Application for ABO-101 for the Treatment of Primary Hyperoxaluria Type 1
-
NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics
-
NewGen Engages OSL to Execute Strategic Investment in Digital Assets
-
AleAnna Announces Signing of Gas Sale Contract with Shell Energy Europe
-
PyroGenesis Announces Debt-to-Equity Conversion of Client Receivable
-
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
-
Climb Bio to be Added to the Nasdaq Biotechnology Index
-
FactSet Reports Results for First Quarter 2025
-
Tilray Brands, Inc. to Announce Second Quarter Fiscal Year 2025 Financial Results on January 9, 2025
-
Conavi Medical Reports Fiscal 2024 Financial Results and Operational Highlights
-
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
-
OTC Markets Group Welcomes Metaplanet Inc. to OTCQX
-
Alliance Witan PLC - Net Asset Value
-
Resolutions of the extraordinary general meeting of Enefit Green AS
-
NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics
-
Alamos Gold Announces Renewal of Normal Course Issuer Bid
-
Kimco Realty® Invites You to Join Its Fourth Quarter Earnings Conference Call
-
Fixing of coupon rates - Nykredit Realkredit A/S
-
SIKA AG signs license agreement on Photocat Bitumen technology to combat Air Pollution
-
Valoe Extends the Subscription Period of the Convertible Bond 1/2023
-
VEON Completes the Move of its Headquarters to Dubai
-
VEON Completes the Move of its Headquarters to Dubai
-
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
-
Hut 8’s Strategic Bitcoin Reserve Surpasses $1 Billion in Market Value with Purchase of $100 Million of Bitcoin
-
Form 8.5 (EPT/RI) - Brown (N.) Group plc


